Recombinant intetferon-y (rlFN-y) therapy has become an effective form of prophylaxis for patients with chronic granulomatous disease (CGD). Preliminary studies with CGD suggested that r1FN-y treatment enhanced phagocyte oxidase activity and increased superoxide (O,-) production. We evaluated several aspects of neutrophil NADPH oxidase activity in 19 CGD patients (representing all four known types of CGD) receiving prolonged rlFN-y therapy (6 t o 27 months). In contrast t o earlier studies, we failed t o detect any improvement in neutrophil NADPH oxidase activity in 18 of the 19 CGD patients as determined by (1) intact cell 0,-production (continuous assay), (2) nitroblue tetrazolium (NBT) staining, (3) cytochrome b , spectroscopy, and (4) activity levels of cytosol and membrane oxidase components using a cell-free activation system. One patient with a variant form of X-linked CGD had a transient increase in neutrophil 0,-production HRONIC GRANULOMATOUS disease (CGD) is a C rare inherited disorder characterized by recurrent pyogenic infections.' Bacterial killing is impaired because of an inability of phagocytic cells to convert molecular oxygen into superoxide (O,-) by an enzyme known as NADPH oxidase.' Recently, it has become apparent that the oxidase is a complex multicomponent enzyme system that includes several cytosolic components and a unique membranebound heterodimeric cytochrome b (termed cytochrome b558).1 It is therefore not surprising that CGD, like many other inherited diseases, is actually a heterogeneous group of disorders, each with a different genetic defect affecting a separate component of the oxidase. The majority of patients (55% of cases) have the classic X-linked form of CGD due to a complete deficiency of the 91-Kd glycoprotein subunit (gp91-phox) of cytochrome b'B2 (CGD type following 3 months of IIFN-y therapy. However, this was not sustained, and was not associated with any change in cytochrome b levels. In some patients, r1FN-y therapy was associated with the appearance of a small subset of circulating monocytes (1% t o 20%) that were NBT-positive. Although the functional significance of this monocyte subpopulation needs t o be determined, these results suggest that one possible mechanism by which r1FN-y may benefit COD patients is by partially correcting the respiratory burst defect in a subset of monocytes. We conclude that the clinical benefit of prolonged rlFN-y therapy in the vast majority of CGD patients is not due t o enhanced neutrophil NADPH oxidase activity. The mechanism of action of rlFN-y in most CGD patients remains unknown.
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Western blot analy~is.'~ Earlier studies with monocytes from these two patients had demonstrated increased gp91-phox mRNA expression following in vitro administration of rIFN-y.I3 More recent studies involving these same two CGD patients suggest that the respiratory burst defect was partially corrected by IFN-y at the level of the myeloid progenitor ce11.I6 Although these preliminary studies suggested a possible mechanism of action for rIFN-y in CGD, they were limited by the brief duration of rIFN-y administration and the number of patients studied.
A recently completed multicenter, double-blind, placebocontrolled randomized phase I11 study of 128 CGD patients demonstrated that prolonged prophylactic rIFN-y therapy led to a 70% reduction in the relative risk of serious infections for both X-linked and autosomal recessive patients." A critical question that remains unanswered by this study is the mechanism of action of rIFN-y in CGD. In contrast to earlier studies, there was no correlation in the phase I11 study between clinical benefit from rIFN-y administration and either enhanced neutrophil (or monocyte) 0,-production (discontinuous assay) or in vitro S aurew bacterial killing.
To investigate further the effects of rIFN-y in CGD, we prospectively examined several aspects of neutrophil respiratory burst activity (including cell-free NADPH oxidase activity) in 19 CGD patients after prolonged rIFN-y therapy (6 to 27 months). All four known phenotypes of CGD were represented in this study, as well as two patients with a variant form of X-linked CGD.
MATERIALS AND METHODS
Patient population. All CGD patients were studied at the General Clinical Research Center of The Scripps Research Institute. Sixteen patients participated in the double-blind, placebocontrolled randomized phase 111 study," while four patients received rIFN-y under a compassionate protocol. One of the patients enrolled in the phase 111 study could not be reevaluated after entering the study because of recurrent infections and a resulting inability to travel to the study center. Clinical data from this patient are included, but follow-up neutrophil studies were not performed. Informed consent was obtained from all patients according to protocols approved by the Scripps Human Subjects Committee. Fourteen males and five females with a mean age of 11.8 years were studied. The diagnosis of CGD was established before rIFN-y therapy according to the entry criteria of the randomized study (02-production I 20% of normal and an abnormal nitroblue tetrazolium [NBT] test).17 Each patient was classified according to pattern of inheritance (X-linked or autosomal recessive) and deficiency of one of the known oxidase components (gp91-, p22-, p47-, or p67-pho.x) as determined by cytochrome b spectroscopy," Northern blot analysis of p22-and gp91-phox mRNA,6 cytosol complementation st~dies,'~ and (in some cases) immunoblot analysis? All patients received rIFN-y subcutaneously three times per week (0.05 mg/m2/dose) for periods of 6 to 27 months. Seventeen of the 19 patients were on daily antibiotic prophylaxis throughout the study; none of the patients received corticosteroids.
Intact cell 0,-assays and cytochrome b measurements were performed on neutrophils (> 95% purity) isolated from whole blood by a previously published method.*' Cytosol and plasma membranes, used for Superoxide and cytochrome b, measurements.
cell-free oxidase activation, were prepared from unstimulated neutrophils collected by leukapheresis and fractionated as described elsewhere.'* The rates of 0,-production by intact neutrophils in suspension and by neutrophil membranes and cytosol in the cell-free activation system were determined by measuring the kinetics of superoxide dismutase (SOD)-inhibitable reduction of ferricytochrome c. For intact neutrophils, cells were stimulated with phorbol myristate acetate (PMA; final concentration, 200 ng/mL) as previously described.2' NADPH oxidase activity in a cell-free system was determined with 40 kmol/L sodium dodecyl sulfate (SDS) using a previously reported method."
Neutrophil cytochrome b,,, levels were determined by dithionite difference spectroscopy as previously described" In patient M.P., with a variant form of X-linked CGD (X91-), cytochrome b spectroscopy was performed on solubilized neutrophil membranes using the same method.
The reduction of NBT dye by neutrophils and monocytes after stimulation with PMA (final concentration, 200 ng/mL) was performed using a modification of a previously published method.u The percentage of NBT-positive cells was determined by light microscopy after counting 200 or more neutrophils (or 250 monocytes). In patients with variant X-linked CGD, the staining intensity of the patient's NBT-positive cells compared with control cells was also determined.
NBT slide tesf.
RESULTS
The results of rIFN-y therapy in CGD have recently been reported." The 16 patients from Scripps Clinic entered in the phase I11 study are included in that report. Among the eight patients eventually found to be on rIFN-y, there were a total of five serious infections? (primary and recurrent) compared with 10 infections in the eight patients receiving placebo. In terms of the number of infections, the Scripps patients were similar to the larger group of CGD patients reported in the phase I11 study.
Neutrophil superoxide production and cytochrome b levels. The effect of prolonged rIFN-y therapy on intact neutrophil 0,-production and cytochrome b levels is shown in Table 1 . In contrast to earlier st~dies,'~.'~ 0; production was measured using a sensitive continuous assay. Despite prolonged rIFN-y therapy varying from 6 to 27 months, only one of the 19 CGD patients (D.H.) demonstrated any appreciable enhancement of neutrophil 0,-production. This patient has a variant form of X-linked CGD (X91-) and showed a transient fourfold increase in 0,-production after 3 months of therapy. However, this increase was not sustained based on reevaluation at 9 months of therapy. None of the CGD patients, regardless of whether they had absent, diminished, or normal levels of neutrophil cytochrome b, showed any significant change in neutrophil cytochrome b levels following prolonged rIFN-y therapy.
The effects of prolonged rIFN-y therapy (3 to 16 months) on the activity of the cytosol and membrane components of NADPH oxidase are shown in Table 2 . Cytosol activity in neutrophils from five CGD patients studied (two with cytochrome b deficiency [X91-and A22"], two with p47-phox deficiency [A47"], and -(2 one with p67-phox deficiency [A67"]) did not change with rIFN-y therapy varying from 3 to 16 months. Similarly, the membrane activity in neutrophils from five CGD patients studied (two with cytochrome b deficiency [X9l0 and A22"], two with p47-phox deficiency [A47"], and one with p67-phox deficiency [A67"]) was not influenced by rIFN-y administration of 3 to 16 months.
Serial NBT slide tests were performed prospectively to assess respiratory burst activity in individual neutrophils and monocytes. Results from 15 patients entered in the randomized phase I11 study are shown in Table 3 . In six of eight patients eventually found to be on rIFN-y therapy, 1% to 20% of peripheral blood monocytes became NBT-positive (and remained so) after 3 to 9 months of treatment. The neutrophils of these patients remained NBT-negative during rIFN-y therapy. The acquisition of peripheral blood NBT-positive monocytes during rIFN-y therapy did not correlate with a particular type of NBT slide rests. CGD. None of the seven patients on placebo developed NBT-positive monocytes; two of these patients with A67" CGD were tested 5 months after switching to IFN-y therapy at the end of the phase I11 study and developed 2% to 3% NBT-positive monocytes. Examples of NBT-positive monocytes are illustrated in Fig 1. One of the A67" CGD patients described above also developed a few weakly NBT-positive neutrophils (2%) with an atypical perinuclear (*) in text for definition of CGD subtypes. tBefore rlFN-y treatment, this patient had strongly NBT-positive neutrophils (5% to 12%) and monocytes (2% to 5%). which did not change following rlFN-y therapy.
*Based on intensity of NBT-staining, this patient had a transient response to rlFN-y treatment.
For Serial NBT tests from the two patients with X91-(variant) CGD were also examined before and during rIFN-y therapy. One of these patients (M.P., on the phase I11 rIFN-y arm) had a subset of strongly NBT-positive neutrophils (5% to 10%) and monocytes (2% to 5%) before treatment, which did not change despite prolonged rIFN-y therapy (27 months). In the second patient (D.H., on compassionate rIFN-y), 100% of the neutrophils and monocytes were weakly NBT-positive before rIFN-y therapy. Following 3 months of IFN-y therapy, there was a significant increase in the intensity of NBT staining. As with the intact neutrophil 0,-measurements described above, these changes were transient and were not present after 9 months of IFN-y therapy. Furthermore, they were never associated with any significant change in cytochrome b levels.
DISCUSSION
In this study, we evaluated several aspects of neutrophil respiratory burst activity in 19 CGD patients during prolonged rIFN-y therapy. All four major genetic types of CGD (X9lo, A22", A47", and A677 were studied, including two patients with a variant form of X-linked CGD (X91-). Despite prolonged continuous rIFN-y therapy, none of the 19 patients showed a sustained improvement in circulating neutrophil NADPH oxidase function as determined by (1) intact cell 0,-production, (2) serial NBT slide tests, (3) cytochrome b,,, spectral levels, or (4) membrane and cytosol activity in the cell-free oxidase activation system. Only one patient with a variant form of X-linked CGD demonstrated a transient fourfold increase in neutrophil 0,-production after 3 months of rIFN-y therapy. However, despite continued rIFN-y therapy, this was unsustained; it was also never associated with any change in cytochrome b,,, levels or in cell-free oxidase activity. Although some select CGD patients may have increased phagocyte 0,-production following in vivo rIFN-y admini~tration,'~ this does not appear to be the case in all patients with X-linked variant CGD (X91-). This discrepancy may be due to the heterogeneity of the genetic defects now known to be responsible for cytochrome b-deficient CGD.3-S*6-8 It is possible that point mutations involving the gp91-phox promoter regionz4 may be more responsive to rIFN-y therapy than those involving the remainder of the gp91-phox gene.
Our investigations with rIFN-y therapy are in agreement with the results of the recently reported phase I11 study in which there was no correlation between clinical benefit of rIFN-y and enhanced neutrophil 0; production." The critical question that remains unanswered, therefore, is the mechanism of action of rIFN-y in CGD. Although the functional significance of the circulating subset of NBTpositive monocytes remains to be determined, our results suggest that one mechanism in which rIFN-y may benefit CGD patients is by partially correcting the respiratory burst defect in a subset of peripheral blood monocytes. Since monocytes spend a relatively brief time in circulation before entering tissues, the actual number of NBT-positive monocytes/macrophages may, in fact, be greater than observed in our study. Further studies to characterize these monocytes and to quantitate the percentage of NBT-positive monocytes/macrophages in tissues are required.
Other possible explanations regarding the mechanism of action of rIFN-y in CGD include improved neutrophil microbicidal killing through a mechanism(s) other than the respiratory burst (eg, increased levels of azurophilic granule antimicrobial proteins) or enhanced function of other cells within the immune system such as T and/or B cells. All of these could explain the reported clinical benefit of For personal use only. on August 30, 2017. by guest www.bloodjournal.org From rIFN-y therapy in patients with both autosomal recessive and X-linked CGD.16 Because we only studied circulating neutrophils, we cannot exclude the possibility that rIFN-y may augment the function of adherent neutrophils and/or tissue macrophages. It has already been established that certain cytokines may enhance the respiratory burst of neutrophils adherent to intravascular or extravascular surfaces, but have no effect on neutrophils in suspension.zs It is thus still possible that rIFN-y therapy in CGD enhances the respiratory burst (and possibly other microbicidal mechanisms) of neutrophils resident within tissues.
The institution of rIFN-y prophylaxis represents an important therapeutic advance in the treatment of CGD. Based on our studies, we plan to investigate the effects of rIFN-y on the function of adherent phagocytic cells, as well as on the neutrophil oxygen-independent mechanisms of microbicidal killing. Determining the mechanism of action of rIFN-y may ultimately have important therapeutic implications for other disorders of host defense.
